Beta Bionics, Inc.

Beta Bionics, Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with diabetes who require insulin. Its core product is the iLet, a subcutaneous insulin infusion system that uses adaptive closed-loop algorithms to determine insulin dosing and is designed to simplify diabetes management by reducing the need for manual carb counting. The company began commercializing the iLet in the United States after FDA clearance in May 2023 and is still in the early phase of building its installed base, reimbursement coverage, and commercial infrastructure. Beta Bionics is also developing next-generation products, including a patch pump, a bihormonal configuration of the iLet, and expanded indications such as type 2 diabetes.

−69,9 %

55,4 %

−73,0 %

+53,9 %

8.66

7.96

— Beta Bionics, Inc.
	%
Automated insulin delivery systems	70% The iLet insulin pump platform and related system components used to automate insulin dosing.
Disposable consumables	25% Single-use cartridges and infusion sets that are repeatedly purchased after device adoption.
Commercial support services	3% Training, onboarding, technical support, and order assistance provided to users and clinicians.
Development collaborations	2% Collaborative development and commercialization work tied to future diabetes technology programs such as Libre-Beta.

Beta Bionics sells primarily to distributors, pharmacy benefit channels, and other intermediaries that place the iLet...

Endocrinology practicesprimary
Specialist clinics that manage high concentrations of insulin-requiring patients and prescribe the iLet because it simplifies dosing and can improve adoption of automated insulin delivery.
DME distributorsprimary
Durable medical equipment distributors that handle order processing, benefits investigation, and product delivery, making them critical to commercial reach and reimbursement execution.
Pharmacy benefit partnerssecondary
Pharmacy channel intermediaries that support pay-as-you-go reimbursement and broader access, especially as the company shifts mix toward more favorable economics.
People with type 1 diabetesprimary
The core end-user population for the iLet, buying the system because it automates insulin dosing and reduces the burden of carb counting.
Primary care practicesemerging
A future expansion channel that could broaden access beyond specialists and increase addressable patient volume.

Beta Bionics currently generates revenue primarily in the United States, where it launched the iLet commercially after...

•Revenue is concentrated in the United States, where the iLet is commercialized
•Commercial organization, training, and customer support are built for U.S. launch execution
•Manufacturing is centered in Irvine, California, supporting current production needs
•International sales are only a future opportunity, not a current revenue driver
•U.S. reimbursement and payor coverage are key to adoption and channel mix
•Domestic regulatory and competitive conditions have outsized impact on results

Beta Bionics is prioritizing commercial scale-up of the iLet while continuing to invest in product innovation and...

Expand U.S. commercial adoptionshort-term

The company is still early in commercialization, so scaling prescriptions and installed base is essential to building recurring consumable revenue.

Shift mix toward pharmacy benefit coverageshort-term

Management expects pharmacy benefit sales to have more favorable lifetime economics than DME sales and to reduce dependence on a small number of distributors.

Develop next-generation diabetes technologiesmedium-term

New products and indications are needed to sustain differentiation against larger insulin pump competitors and broaden the addressable market.

Scale manufacturing and support infrastructuremedium-term

Commercial growth requires reliable supply, service quality, and operational capacity to avoid bottlenecks and preserve customer trust.

Beta Bionics faces the typical risks of an early commercial medical device company, including limited operating...

high

Customer concentration in DME distribution

A small number of distributors account for a large share of revenue, so loss of one or more partners would quickly affect sales.

Scope: Top four DME distributors represented about 52% of total sales in 2025
Materiality: high

high

Reimbursement and coverage dependence

The iLet’s adoption depends on third-party payor coverage and channel reimbursement, which directly influence patient access and gross margin mix.

Scope: DME and pharmacy benefit coverage strategy
Materiality: high

high

Competition from established insulin pump companies

Larger competitors have greater scale, brand recognition, and distribution, making it harder for Beta Bionics to win share.

Scope: Medtronic, Tandem, Insulet, and alternative diabetes therapies
Materiality: high

high

Regulatory and product safety risk

As a regulated medical device company, adverse safety findings or compliance issues could delay commercialization or damage trust.

Scope: iLet, future patch pump, bihormonal configuration, and software features
Materiality: high

medium

Intellectual property disputes

Patent claims or licensing disputes could increase costs, restrict product features, or delay launches.

Scope: Core device technology and future product candidates
Materiality: medium

Revenue recognition net of variable consideration

Can cause revenue and gross margin to differ from cash collections

Channel mix and gross margin timing

Quarterly gross margin can fluctuate with channel mix

Inventory valuation and obsolescence

Can affect cost of sales and operating results

Royalty obligations

Reduces gross margin as sales scale

Beta Bionics, Inc.

Customer concentration in DME distribution

Reimbursement and coverage dependence

Competition from established insulin pump companies

Regulatory and product safety risk

Intellectual property disputes

BIOMERICA INC

BiomX Inc.

INSULET CORP

BioAtla, Inc.

BIOTRICITY INC.

Embecta Corp.